It has been announced that a new cancer drug, which was pioneered at the Freeman Hospital in Newcastle, will not be made available across England.
Trials found that the drug, called Kadcycla could extend the lives of some breast cancer patients by around six months.
The decision was made by the NHS's drugs advisory body NICE. They say the treatment is too expensive.
But Roche, the company that makes Kadcycla, insist it is affordable.
Here is the reaction from Sir Andrew Dillon, the Chief Executive of NICE and Jennifer Cozzone from the drug's manufacturers, Roche:
The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
Newcastle United assistant manager John Carver said the announcement that Alan Pardew will stay on as manager next season was 'great' for the club.
He said: "He's a top manager and a top coach and he's had to work under some difficult circumstances but what I will say is that everyone's stuck together and been strong."
Speaking about the potential signings of new players this summer, he told ITV Tyne Tees: "I don't think it's rocket science that we need to bring players in, but how many I don't know."
Celebrities travelled far and wide for the Children's Heart Unit charity golf day in Northumberland.
For Newcastle United assistant manager John Carver, there wasn't quite so far to go.
The Close House Hotel, where the event was held, is his local club.
But he said he would have been there, regardless of the distance, to support the charity.
Alan Shearer has voiced his support for Alan Pardew after Newcastle confirmed the manager will continue next season.
The former Newcastle striker was speaking at a charity golf day in Northumberland in aid of the Children's Heart Unit and the Freeman Hospital.
He told ITV Tyne Tees: "You can't sell your best player and not replace him and I think that's why everyone was so unhappy."
Ant and Dec were still celebrating their BAFTAs success as they took part in a charity golf day in Newcastle.
Despite little sleep, the Geordie duo were on form on the fairways, raising money for the Children's Heart Unit at the Freeman hospital in Newcastle.